Novo's 14 GLP-1 Names in Denmark: Poach Before Lilly Lands

On September 21, 2026, Novo Nordisk CEO Mike Doustdar told investors at Capital Markets Day in London that headcount is down about 13,000 in the past year, not the 9,000 announced in the September 2025 restructuring. Roughly 5,000 of those cuts landed in Denmark, on top of a company that already had the world's densest GLP-1 R&D bench. If you recruit for obesity, diabetes, or metabolic disease programs, the next twelve months are the shallowest, most identifiable poaching window Europe has ever offered you.

This piece is the sourcing playbook: who is actually addressable, why the headline number overstates the real pool, and where the survivors (not the leavers) are the higher-value target.

What Novo actually disclosed on September 21, 2026

Novo Nordisk's total workforce now stands at 67,000, down from roughly 78,400 a year ago, with about 5,000 of the reductions concentrated in Denmark. A company spokesperson told BioSpace the 13,000 figure includes the original 9,000 restructuring plus about 4,000 in natural attrition and unfilled roles.

The key facts, in order of what they mean for a recruiter:

• 13,000 net exits in twelve months, versus the 9,000 originally telegraphed in September 2025.
• 5,000 of those in Denmark, per the original restructuring plan. Børsen figures cited by Ritzau show Denmark headcount fell from 33,820 in September 2025 to 26,511 by end of July 2026, a drop of roughly 7,300 in ten months.
• A five-days-a-week return-to-office mandate imposed on survivors, at a company that has just cut roughly 17% of its people.
• Doustdar's turnaround plan promises at least five multi-blockbuster products (over $1B in sales each) before 2030, so R&D is being reshuffled, not shrunk, which creates internal-reassignment flight risk.

The market context matters. Fifteen months ago Novo was Europe's most valuable listed company at $640B; it now ranks seventh at $242B. These are structural cuts against a $100B-a-year GLP-1 market forecast for 2030. Every hire pulled from Bagsværd shows up on somebody else's roadmap.

13,000

Why the recruitable pool is much smaller than 13,000

The "13,000" figure overstates the addressable market because a large slice of it is stale. Novo's own spokesperson attributed part of the additional 4,000 (beyond the original 9,000 plan) to natural attrition and unfilled roles, which means those people already changed employers months ago or were never on the org chart to begin with.

If you build a target list off LinkedIn's "past company: Novo Nordisk" filter without a date bound, you will burn a week on candidates who are already six months into their next job at Lundbeck or Genmab. The rule of thumb:

1. Filter by departure date within 90 days for the leaver pool.
2. Treat anyone who left before Q2 2026 as a market comp signal, not a live lead.
3. Reserve your best outreach for current Novo employees in R&D functions the restructuring is reshuffling.

Attrition-based reductions always front-load the market. By the time the CEO says the number out loud, the first wave has already been absorbed by whichever local competitor moved fastest, which in Copenhagen usually means Gubra, Zealand Pharma, or a Nordic-founded obesity play like Embla.

The real prize: 14 of 17 Denmark GLP-1 experts still sit at Novo

The Denmark GLP-1 talent pool is a monopsony that is only just starting to break, and the target list is tiny enough to work by name. In Refolk's index of professional profiles, only 17 profiles in Denmark carry "GLP-1" in a headline or experience entry, and 14 of those 17 currently sit inside Novo Nordisk. That is 82% of the visible Denmark GLP-1 talent pool concentrated inside one employer.

Twelve of the seventeen live in the Copenhagen Capital Region. One is at Region Hovedstaden. The entire addressable pool sits inside a 30 km radius of Bagsværd.

The exemplar titles from that Denmark pool tell you exactly what search strings to paste into your sourcing tool:

• Global Director, GLP-1 portfolio lead
• Global Associate Director, Sema Diabetes Projects
• Director of Trial Operations 1, GLP-1, CV & Outcomes

These are not generic "scientist" strings. They are Novo-native title conventions, and the moment you paste them into a Boolean builder that expects LinkedIn-style titles, you get almost nothing back. That is the exact gap Refolk closes: you describe the person in plain English ("director-level GLP-1 trial ops in Copenhagen, currently or recently at Novo") and get a ranked shortlist that maps Novo's internal naming to actual profiles.

82%

Where the ex-Novo talent lands (and who you are bidding against)

The receiving side of this migration is not just Eli Lilly. It is a spread of GLP-1 challengers and Nordic-founded obesity plays, and if you do not name them in your outreach you will misprice the offer.

The named absorbers, roughly in order of how aggressively they are hiring against Novo right now:

• Eli Lilly, which opened 2026 with a multi-year Nimbus Therapeutics collaboration worth up to $1.3B for a preclinical obesity therapeutic. Direct absorber of GLP-1 chemistry and preclinical staff.
• Verdiva Bio, Structure Therapeutics, and Viking Therapeutics, all presenting GLP-1 assets at ADA 2026 and actively hiring.
• Roche and Pfizer, both rebuilding metabolic disease benches after late entries to the category.
• Embla, a Danish obesity-care company that already appears in the U.S. GLP-1 talent data and is the natural landing pad for ex-Novo commercial and medical-affairs staff.
• Gubra, the only non-Novo Denmark-based obesity and diabetes scientist employer surfacing with any density in the index. Copenhagen CRO and biotech, the local absorber to watch.

The tell for a smart outbound campaign: the U.S. GLP-1 top-employer list is fragmented (Embla, PlexusDx, Wondr Health, Verdiva Bio, Omada Health, none with more than two profiles). No incumbent owns the U.S. pool the way Novo owns Denmark's. That fragmentation is why the U.S. market is 37.6x larger by profile count but far harder to source through: no single employer filter gets you there.

The RTO mandate is the real poaching lever, not the severance

Focus your outreach on Novo survivors, not leavers, and lead with the return-to-office decree rather than the layoff news. Novo told employees in mid-2026 they must work from the office five days per week. That directive, dropped on a workforce that has just watched roughly 17% of its colleagues leave, is the single most portable retention risk on the Continent.

Why it works better than layoff-based outreach:

• Leavers are already talking to recruiters. A GLP-1 director who took severance in June 2026 has an inbox full of Lilly and Roche pitches. You are the fourteenth email.
• Survivors are angry and unpitched. They kept the job, watched colleagues leave, and now commute five days a week to fill a chair someone else used to sit in. Nobody has messaged them yet with a specific alternative.
• The RTO angle is legal and evergreen. You are not citing anyone's severance package or naming a redundancy list. You are citing a public policy the CEO announced.

The outreach shape that works: name the specific Novo program the person is on (the exemplar titles above are gold for this), acknowledge the RTO shift, and offer a concrete alternative (hybrid, four-day in-office, or a fully remote medical affairs seat at a U.S. buyer). Two sentences, no attachments.

This is where a search-by-description tool earns its keep. Refolk lets you ask for "current Novo Nordisk staff in Bagsværd on semaglutide or cagrilintide programs, director level and below" and returns the actual people, not a keyword-matched sludge of former interns from 2014. That specificity is what lets you write outreach that reads like a colleague wrote it, not a scraper.

Survivors are the higher-value target. They kept the job and watched their friends leave. Nobody has messaged them yet.

A 90-day sourcing plan for biotech recruiters

Run this as a bounded campaign, not an evergreen pipeline, because the Denmark pool will be picked over by Q2 2027. The sequencing:

1. Week 1 to 2: Map the 17. Build a named list of every Denmark GLP-1 profile in your index of choice. Tag by current employer, title, and (if leaver) departure date. A plain-English search will get you there in a session; a Boolean chain across Novo's title conventions will take a week.
2. Week 3 to 4: Segment survivors vs. leavers. Split into (a) currently at Novo, (b) departed within 90 days, (c) departed 90 to 365 days ago. Treat (c) as market intel only.
3. Week 5 to 8: Outreach wave one. Message the 14 current Novo names first, with the RTO angle and a program-specific opener. Message recent leavers in parallel with a specific role, not a "let's connect."
4. Week 9 to 12: Widen to adjacencies. Pull the "obesity" and "cardiometabolic" keyword rings around GLP-1: Gubra, Zealand Pharma, and Copenhagen-based CRO staff. These are your second-choice hires when the primary 14 say no or counter above budget.
5. Ongoing: Monitor U.S. rounds. Novo's U.S. cuts are still staged into early 2027; set alerts for the sites where Novo's U.S. R&D concentrates.

The whole campaign lives or dies on how fast you can convert "person Novo doesn't want to lose" into "person on your calendar." That is a sourcing-speed problem, and it is why the recruiters who move first on the 14 named directors will define the next generation of obesity R&D leadership outside Bagsværd.

FAQ

How many people did Novo Nordisk actually lay off in 2026?

Novo Nordisk disclosed on September 21, 2026 that its workforce is down about 13,000 in the past year, bringing headcount to 67,000. That figure includes the original 9,000-role restructuring announced in September 2025 plus roughly 4,000 in natural attrition and unfilled roles. About 5,000 of the reductions concentrated in Denmark, and U.S. rounds are still being staged.

Where do ex-Novo GLP-1 scientists usually land?

The named absorbers in 2026 are Eli Lilly (via its $1.3B Nimbus Therapeutics obesity collaboration), Structure Therapeutics, Viking Therapeutics, Verdiva Bio, Roche, and Pfizer on the biopharma side. On the Nordic side, Embla and Gubra are the two names surfacing consistently in Refolk's index as local absorbers. Danish emigrés disproportionately land at Nordic-founded obesity plays with U.S. footprints, which is why the U.S. GLP-1 profile list is more fragmented than the Denmark one.

Is it better to poach Novo survivors or recent leavers?

Survivors, in most cases. Leavers already have inboxes full of pitches from Lilly and Roche, and the ones with the strongest CVs were absorbed within weeks of departure. Current Novo employees, especially those subject to the five-days-a-week return-to-office mandate imposed in 2026, are the higher-value and less-contacted target. Lead your outreach with the RTO angle and a specific program, not with the layoff news.

How do I actually source the 17 GLP-1 profiles in Denmark?

Skip generic Boolean strings. Novo uses internal title conventions (for example "Global Associate Director, Sema Diabetes Projects") that do not match LinkedIn's title taxonomy. A plain-English search tool like Refolk lets you describe the person ("director-level GLP-1 or semaglutide staff in the Copenhagen Capital Region, currently at Novo Nordisk") and returns the matches across LinkedIn, GitHub, and the open web without you having to reverse-engineer the company's naming.